Your browser doesn't support javascript.
loading
Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer.
Peuker, Kenneth; Strigli, Anne; Tauriello, Daniele V F; Hendricks, Alexander; von Schönfels, Witigo; Burmeister, Greta; Brosch, Mario; Herrmann, Alexander; Krüger, Sandra; Nitsche, Jessica; Juznic, Lea; Geissler, Marc Marius; Hiergeist, Andreas; Gessner, André; Wirbel, Jakob; Ponnudurai, Ruby Priyadarshini; Tunger, Antje; Wehner, Rebekka; Stange, Daniel E; Weitz, Jürgen; Aust, Daniela E; Baretton, Gustavo B; Schmitz, Marc; Röcken, Christoph; Hampe, Jochen; Hinz, Sebastian; Zeller, Georg; Chavakis, Triantafyllos; Schafmayer, Clemens; Batlle, Eduard; Zeissig, Sebastian.
Affiliation
  • Peuker K; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Strigli A; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Tauriello DVF; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri i Reixac 10, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08028 Barcelona, Spain.
  • Hendricks A; Department of General and Thoracic Surgery, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany; Department of General Surgery, University Medicine Rostock, 18507 Rostock, Germany.
  • von Schönfels W; Department of General and Thoracic Surgery, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany.
  • Burmeister G; Department of General and Thoracic Surgery, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany; Department of General Surgery, University Medicine Rostock, 18507 Rostock, Germany.
  • Brosch M; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Herrmann A; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Krüger S; Institute of Pathology, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany.
  • Nitsche J; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Juznic L; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Geissler MM; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Hiergeist A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93042 Regensburg, Germany.
  • Gessner A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, 93042 Regensburg, Germany.
  • Wirbel J; Structural and Computational Biology Unit, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.
  • Ponnudurai RP; Structural and Computational Biology Unit, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.
  • Tunger A; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany.
  • Wehner R; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany.
  • Stange DE; National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany; Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, 01307 Dresden, Germany; German Cancer Consortium (DKTK), Partner Site
  • Weitz J; National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany; Department of Visceral, Thoracic and Vascular Surgery, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, 01307 Dresden, Germany; German Cancer Consortium (DKTK), Partner Site
  • Aust DE; Institute of Pathology, University Medical Center Dresden, Technische Universität (TU) Dresden, Dresden, Germany; Tumor and Normal Tissue Bank of the University Cancer Center (UCC), University Medical Center Dresden, Technische Universität (TU) Dresden, Dresden, Germany.
  • Baretton GB; Institute of Pathology, University Medical Center Dresden, Technische Universität (TU) Dresden, Dresden, Germany.
  • Schmitz M; Institute of Immunology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany; National Center for Tumor Diseases (NCT), Partner Site Dresden, 01307 Dresden, Germany; German Cancer Consortium (DKTK), Partner Site Dresden, Dresden, Germany; German Cancer Resea
  • Röcken C; Institute of Pathology, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany.
  • Hampe J; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Hinz S; Department of General and Thoracic Surgery, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany; Department of General Surgery, University Medicine Rostock, 18507 Rostock, Germany.
  • Zeller G; Structural and Computational Biology Unit, European Molecular Biology Laboratory, 69117 Heidelberg, Germany.
  • Chavakis T; Institute for Clinical Chemistry and Laboratory Medicine, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany.
  • Schafmayer C; Department of General and Thoracic Surgery, University Medical Center Schleswig-Holstein, 24105 Kiel, Germany; Department of General Surgery, University Medicine Rostock, 18507 Rostock, Germany.
  • Batlle E; Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri i Reixac 10, 08028 Barcelona, Spain; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 08028 Barcelona, Spain; ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain.
  • Zeissig S; Department of Medicine I, University Medical Center Dresden, Technische Universität (TU) Dresden, 01307 Dresden, Germany; Center for Regenerative Therapies Dresden (CRTD), Technische Universität (TU) Dresden, 01307 Dresden, Germany. Electronic address: sebastian.zeissig@tu-dresden.de.
Immunity ; 55(4): 701-717.e7, 2022 04 12.
Article in En | MEDLINE | ID: mdl-35364006
ABSTRACT
Bacterial sensing by intestinal tumor cells contributes to tumor growth through cell-intrinsic activation of the calcineurin-NFAT axis, but the role of this pathway in other intestinal cells remains unclear. Here, we found that myeloid-specific deletion of calcineurin in mice activated protective CD8+ T cell responses and inhibited colorectal cancer (CRC) growth. Microbial sensing by myeloid cells promoted calcineurin- and NFAT-dependent interleukin 6 (IL-6) release, expression of the co-inhibitory molecules B7H3 and B7H4 by tumor cells, and inhibition of CD8+ T cell-dependent anti-tumor immunity. Accordingly, targeting members of this pathway activated protective CD8+ T cell responses and inhibited primary and metastatic CRC growth. B7H3 and B7H4 were expressed by the majority of human primary CRCs and metastases, which was associated with low numbers of tumor-infiltrating CD8+ T cells and poor survival. Therefore, a microbiota-, calcineurin-, and B7H3/B7H4-dependent pathway controls anti-tumor immunity, revealing additional targets for immune checkpoint inhibition in microsatellite-stable CRC.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Microbiota Limits: Animals Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2022 Type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Microbiota Limits: Animals Language: En Journal: Immunity Journal subject: ALERGIA E IMUNOLOGIA Year: 2022 Type: Article Affiliation country: Germany